		LTH AND HUMAN SER	VICES	F) 9539
DISTRICT ADDRESS AND PHON	ONE NUMBER		DATE(S) OF INSPECTION	
Bothell, WA	ve SE Suite 210		5/28/2019-6/13/2019* FEI NUMBER	
	0 Fax: (425)302-0404		5089725	
NAME AND TITLE OF INDIVIDUA	L TO WHOM REPORT ISSUED			
	, President and CEO			
FIRM NAME		STREET ADDRESS	327	
Pharmacy and	Drug Corporation dba Key Compounding Center	530 S 336th St		
CITY, STATE, ZIP CODE, COUN				
rederal way,	wA 98003-6383 Producer products		r of sterile and non-sterile s	
observations, and do observation, or have action with the FDA questions, please con	observations made by the FDA representative not represent a final Agency determination re implemented, or plan to implement, corrective representative(s) during the inspection or substact FDA at the phone number and address ab	egarding your compliance or action in response to ar mit this information to F.	e. If you have an objection re observation, you may discu	garding an ss the objection or
OBSERVATION	CTION OF YOUR FIRM WE OBSERVED:			
You used a non-pharmaceutical grade component in the formulation of a drug product.				
Specifically,				
that is not	our firm produced Potassium Bromide labeled as pharmaceutical or FCC graph (4).			
5/28/2019(Tue),	5/29/2019(Wed), 5/30/2019(Thu), 6/06/2019(Thu), 6/07/2019(Fri),	[8] [8] [8] [8] [8] [8] [8] [8] [8] [8]	5/03/2019(Mon), 6/04	/2019(Tue),
Peter S Kessler Investigator Signed By: Peter S. Kes Date Signed: 06-13-201	usion -S 9 07:28:26			
SEE REVERSE	EMPLOYEE(S) SIGNATURE Andrew K Haack, Investigat		1	DATE ISSUED 6/13/2019
OF THIS PAGE	Peter S Kessler, Investiga		Andrew K Haack Investigator Investigator Disco Signed: 06-13-2019 07:27-43	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE I	NSPECTIONAL OBSERV	'ATIONS	PAGE 1 of 1 PAGES